Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL248062 | 0.98 | TSHR (0.44) | TSHRALDH1A1THRBPOLBAPEX1 | |
| Sulfuric Acid SCHEMBL8720200 | 0.93 | TSHR (0.40) | TSHRALDH1A1THRB | |
| SCHEMBL547837 | 0.88 | ALDH1A1 (0.39) | TSHRALDH1A1THRB | |
| SCHEMBL14994268 | 0.82 | TSHR (0.44) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL2939730 | 0.80 | THRB (0.44) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL10495130 | 0.80 | THRB (0.48) | TSHRALDH1A1THRBPOLBAPEX1 | |
| Hydrochloric Acid SCHEMBL5538296 | 0.79 | THRB (0.47) | TSHRALDH1A1THRBPOLBAPEX1 | |
| SCHEMBL4948171 | 0.79 | THRB (0.43) | TSHRALDH1A1THRBMGAMGAA | |
| Hydrochloric Acid SCHEMBL1237638 | 0.79 | THRB (0.43) | TSHRALDH1A1THRBMGAMGAA | |
| SCHEMBL57880 | 0.78 | TSHR (0.52) | TSHRALDH1A1THRBPOLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114173763-A | Lacosamide pharmaceutical composition and pharmaceutical preparation thereof | 上海奥科达生物医药科技有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-112043681-A | Lacosamide pharmaceutical composition and pharmaceutical preparation thereof | 上海奥科达生物医药科技有限公司 | 2020-12-08 | — | — | CN | claimed |
| US-8540956-B2 | Method for preparing titanium-silicalite molecular sieve and method for preparing cyclohexanone oxime using titanium-silicalite molecular sieve | CHINA PETROCHEMICAL DEVELOPMENT CORPORATION (TW) | 2013-09-24 | — | — | US | claimed |
| US-20110144328-A1 | METHOD FOR PREPARING TITANIUM-SILICALITE MOLECULAR SIEVE AND METHOD FOR PREPARING CYCLOHEXANONE OXIME USING TITANIUM-SILICALITE MOLECULAR SIEVE | CHINA PETROCHEMICAL DEVELOPMENT CORPORATION (TW) | 2011-06-16 | — | — | US | claimed |
| WO-2010054800-A1 | TRIBLOCK COPOLYMER GELATORS | STICHTING DUTCH POLYMER INSTITUTE (NL) | 2010-05-20 | — | — | WO | claimed |
| EP-2186858-A1 | Triblock copolymer gelators | Wageningen Universiteit (NL) | 2010-05-19 | — | — | EP | claimed |
| EP-1814924-A2 | AMPHIPHILIC STAR BLOCK COPOLYMERS | FIRMENICH SA (CH) | 2007-08-08 | — | — | EP | claimed |
| US-20070160561-A1 | AMPHIPHILIC STAR BLOCK COPOLYMERS | FIRMENICH SA (CH) | 2007-07-12 | — | — | US | claimed |
| EP-1345594-B1 | THERMOFORMABLE SOLID PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF IVABRADINE | SERVIER LAB (FR) | 2007-01-24 | — | — | EP | claimed |
| WO-2006038110-A2 | AMPHIPHILIC STAR BLOCK COPOLYMERS | FIRMENICH SA (CH) | 2006-04-13 | — | — | WO | claimed |
| EP-0583319-B1 | LIPASE-CATALYZED ESTER HYDROLYSIS | NOVO NORDISK AS (DK) | 1995-07-12 | — | — | EP | claimed |
| US-4009317-A | Glass fiber coated with a size comprising emulsified clad particles of poly(methyl methacrylate) | OWENS-CORNING FIBERGLAS CORPORATION (US) | 1977-02-22 | — | — | US | claimed |
| CN-115023431-B | Triterpene compounds, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by member 1 of the nuclear receptor subfamily 4 | 藤济(厦门)生物医药科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20240016711-A1 | Perfume Compositions | GIVAUDAN SA (CH) | 2024-01-18 | — | — | US | disclosed |
| US-20240016712-A1 | Perfume Compositions | GIVAUDAN SA (CH) | 2024-01-18 | — | — | US | disclosed |
| CN-117203196-A | PDE4 degrading agents, pharmaceutical compositions and therapeutic applications | 拜欧斯瑞克斯公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-0583319-A1 | LIPASE-CATALYZED ESTER HYDROLYSIS. | NOVO NORDISK AS (DK) | 1994-02-23 | — | — | EP | disclosed |
| WO-1992019808-A1 | LIPASE-CATALYZED ESTER HYDROLYSIS | NOVO NORDISK A/S (DK) | 1992-11-12 | — | — | WO | disclosed |
| EP-0203776-A2 | Coloring-time controlling layer | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1986-12-03 | — | — | EP | disclosed |
| US-4505797-A | Ion-exchange membranes reinforced with non-woven carbon fibers | IONICS, INCORPORATED (US) | 1985-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160561-A1 | AMPHIPHILIC STAR BLOCK COPOLYMERS | ABCB4, ABCB7, ABCC5 | TSHR 1732/4885ALDH1A1 3042/4885THRB 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.